Singapore – VistaGen Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system. Recently, it announced that the Japanese Patent Office has issued a Notice of Allowance for a patent covering certain methods for producing blood cells, platelets and bone marrow stem cells.

It says the Japanese patent is like U.S. Patent awarded in December 2017.